

Raymond Lai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5728200/publications.pdf>

Version: 2024-02-01

76
papers

1,864
citations

236612

25
h-index

276539

41
g-index

76
all docs

76
docs citations

76
times ranked

3246
citing authors

#	ARTICLE	IF	CITATIONS
1	Silibinin induces immunogenic cell death in cancer cells and enhances the induced immunogenicity by chemotherapy. <i>BioImpacts</i> , 2023, 13, 51-61.	0.7	6
2	Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands. <i>BioImpacts</i> , 2022, , .	0.7	4
3	BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL. <i>Cancers</i> , 2022, 14, 151.	1.7	2
4	N-myristoyltransferase proteins in breast cancer: prognostic relevance and validation as a new drug target. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 79-87.	1.1	10
5	Gene Methylation and Silencing of WIF1 Is a Frequent Genetic Abnormality in Mantle Cell Lymphoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 893.	1.8	1
6	Three-Dimensional Reconstructed Bone Marrow Matrix Culture Improves the Viability of Primary Myeloma Cells In-Vitro via a STAT3-Dependent Mechanism. <i>Current Issues in Molecular Biology</i> , 2021, 43, 313-323.	1.0	3
7	Identification and Characterization of Cancer Stem-Like Cells in ALK-Positive Anaplastic Large Cell Lymphoma Using the SORE6 Reporter. <i>Current Issues in Molecular Biology</i> , 2021, 43, 543-557.	1.0	5
8	The Dual Role of Autophagy in Crizotinib-Treated ALK+ ALCL: From the Lymphoma Cells Drug Resistance to Their Demise. <i>Cells</i> , 2021, 10, 2517.	1.8	5
9	Flow Cytometric Detection of the Double-Positive (CD4+CD8+)/PD-1bright T-Cell Subset Is Useful in Diagnosing Nodular Lymphocyte-Predominant Hodgkin Lymphoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, , .	1.2	3
10	Crizotinib Resistance Mediated by Autophagy Is Higher in the Stem-Like Cell Subset in ALK-Positive Anaplastic Large Cell Lymphoma, and This Effect Is MYC-Dependent. <i>Cancers</i> , 2021, 13, 181.	1.7	9
11	Gene Expression Profiling of Mycosis Fungoides in Early and Tumor Stageâ€”A Proof-of-Concept Study Using Laser Capture/Single Cell Microdissection and NanoString Analysis. <i>Cells</i> , 2021, 10, 3190.	1.8	1
12	NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma. <i>Cancers</i> , 2019, 11, 1119.	1.7	6
13	Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma. <i>Cancers</i> , 2019, 11, 248.	1.7	26
14	Development of Traceable Rituximab-Modified PEO-Polyester Micelles by Postinsertion of PEG-phospholipids for Targeting of B-cell Lymphoma. <i>ACS Omega</i> , 2019, 4, 18867-18879.	1.6	5
15	Epidemiology of Post-Transplant Lymphoproliferative Disorders in Children with Solid Organ Transplant over 34 Years of a Single Center Experience. <i>Blood</i> , 2019, 134, 1602-1602.	0.6	1
16	New MYC IHC Classifier Integrating Quantitative Architecture Parameters to Predict MYC Gene Translocation in Diffuse Large B-Cell Lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 54-63.	0.6	4
17	The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years. <i>Transplantation</i> , 2018, 102, 1553-1562.	0.5	59
18	Hypoxia Induces the Acquisition of Cancer Stem-like Phenotype Via Upregulation and Activation of Signal Transducer and Activator of Transcription-3 (STAT3) in MDA-MB-231, a Triple Negative Breast Cancer Cell Line. <i>Cancer Microenvironment</i> , 2018, 11, 141-152.	3.1	26

#	ARTICLE	IF	CITATIONS
19	Functional Plasticity of Gamma Delta T Cells and Breast Tumor Targets in Hypoxia. <i>Frontiers in Immunology</i> , 2018, 9, 1367.	2.2	30
20	Phosphorylation of Sox2 at Threonine 116 is a Potential Marker to Identify a Subset of Breast Cancer Cells with High Tumorigenicity and Stem-Like Features. <i>Cancers</i> , 2018, 10, 41.	1.7	10
21	Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model. <i>Cancers</i> , 2018, 10, 206.	1.7	16
22	Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt/ β -catenin/MYC/Sox2 axis in ALK-positive anaplastic large-cell lymphoma. <i>BMC Cancer</i> , 2018, 18, 361.	1.1	20
23	The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients. <i>Oncotarget</i> , 2018, 9, 10698-10713.	0.8	0
24	FOXM1 and the NPM-ALK/STAT3 Axis Form a Novel Positive Feedback Loop in Promoting the Oncogenesis of ALK-Positive Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2018, 132, 3921-3921.	0.6	0
25	Micellar nano-carriers for the delivery of STAT3 dimerization inhibitors to melanoma. <i>Drug Delivery and Translational Research</i> , 2017, 7, 571-581.	3.0	14
26	Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy. <i>Pharmaceutical Biology</i> , 2017, 55, 729-739.	1.3	67
27	High expression of β -catenin contributes to the crizotinib resistant phenotype in the stem-like cell population in neuroblastoma. <i>Scientific Reports</i> , 2017, 7, 16863.	1.6	10
28	STAT1 β enhances STAT1 function by protecting STAT1 β from degradation in esophageal squamous cell carcinoma. <i>Cell Death and Disease</i> , 2017, 8, e3077-e3077.	2.7	19
29	STAT3 but Not HIF-1 β Is Important in Mediating Hypoxia-Induced Chemoresistance in MDA-MB-231, a Triple Negative Breast Cancer Cell Line. <i>Cancers</i> , 2017, 9, 137.	1.7	26
30	High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer. <i>Oncotarget</i> , 2017, 8, 28101-28115.	0.8	23
31	PDGFR β Regulates Follicular Cell Differentiation Driving Treatment Resistance and Disease Recurrence in Papillary Thyroid Cancer. <i>EBioMedicine</i> , 2016, 12, 86-97.	2.7	28
32	miR-200b induces cell cycle arrest and represses cell growth in esophageal squamous cell carcinoma. <i>Carcinogenesis</i> , 2016, 37, 858-869.	1.3	29
33	A positive feedback loop involving the Wnt/ β -catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2016, 9, 120.	6.9	34
34	The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers. <i>Scientific Reports</i> , 2016, 6, 33710.	1.6	35
35	The PI3K/AKT/c-MYC Axis Promotes the Acquisition of Cancer Stem-Like Features in Esophageal Squamous Cell Carcinoma. <i>Stem Cells</i> , 2016, 34, 2040-2051.	1.4	63
36	The Opposing Function of STAT3 as an Oncoprotein and Tumor Suppressor Is Dictated by the Expression Status of STAT3 β in Esophageal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 691-703.	3.2	46

#	ARTICLE	IF	CITATIONS
37	Oxidative stress induces the acquisition of cancer stem-like phenotype in breast cancer detectable by using a Sox2 regulatory region-2 (SRR2) reporter. <i>Oncotarget</i> , 2016, 7, 3111-3127.	0.8	27
38	CD3 T-Cell Infiltrates at Diagnosis Predicts Overall Survival in Solid Organ Transplant Recipients with Post-Transplant Lymphoproliferative Disorders (PTLD). <i>Blood</i> , 2016, 128, 1873-1873.	0.6	0
39	STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma. <i>Blood</i> , 2015, 126, 336-345.	0.6	22
40	Triple negative breast cancers comprise a highly tumorigenic cell subpopulation detectable by its high responsiveness to a Sox2 regulatory region 2 (SRR2) reporter. <i>Oncotarget</i> , 2015, 6, 10366-10373.	0.8	20
41	Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, 593-607.	1.6	48
42	Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 57, 1-9.	0.6	15
43	Elevated <i>ARG1</i> expression in primary monocytes-derived macrophages as a predictor of radiation-induced acute skin toxicities in early breast cancer patients. <i>Cancer Biology and Therapy</i> , 2015, 16, 1281-1288.	1.5	9
44	Loss of miR-200b promotes invasion via activating the Kindlin-2/integrin β 1/AKT pathway in esophageal squamous cell carcinoma: An E-cadherin-independent mechanism. <i>Oncotarget</i> , 2015, 6, 28949-28960.	0.8	41
45	Morphologic Evolution in Post-Transplant Lymphoproliferative Disorders (PTLD): A Clinicopathologic Case Series. <i>Blood</i> , 2015, 126, 5008-5008.	0.6	0
46	Correlation of STAT1 with Apoptosis and Cell-Cycle Markers in Esophageal Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e113928.	1.1	25
47	Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarrays. <i>Breast Cancer Research</i> , 2014, 16, 470.	2.2	13
48	STAT3 in Cancer—Friend or Foe?. <i>Cancers</i> , 2014, 6, 1408-1440.	1.7	137
49	YB-1 regulates Sox2 to coordinately sustain stemness and tumorigenic properties in a phenotypically distinct subset of breast cancer cells. <i>BMC Cancer</i> , 2014, 14, 328.	1.1	21
50	β -Catenin, a Sox2 binding partner, regulates the DNA binding and transcriptional activity of Sox2 in breast cancer cells. <i>Cellular Signalling</i> , 2014, 26, 492-501.	1.7	26
51	Expression of Nucleoside Transporters and Deoxycytidine Kinase Proteins in Muscle Invasive Urothelial Carcinoma of the Bladder: Correlation with Pathological Response to Neoadjuvant Platinum/Gemcitabine Combination Chemotherapy. <i>Journal of Urology</i> , 2014, 191, 35-39.	0.2	6
52	Methylation of <i>miR-155-3p</i> in mantle cell lymphoma and other non-Hodgkin's lymphomas. <i>Oncotarget</i> , 2014, 5, 9770-9782.	0.8	30
53	Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma. <i>Biomaterials</i> , 2013, 34, 8718-8725.	5.7	33
54	Nodular lymphocyte predominant Hodgkin's lymphoma of the cervix: A case report of a rare entity. <i>Gynecologic Oncology Case Reports</i> , 2013, 4, 4-6.	0.9	1

#	ARTICLE	IF	CITATIONS
55	The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update. <i>Therapeutic Advances in Hematology</i> , 2013, 4, 119-131.	1.1	36
56	Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy. <i>Journal of Biomedical Materials Research - Part A</i> , 2013, 102, n/a-n/a.	2.1	13
57	Biological and clinical significance of GSK-3beta in mantle cell lymphoma—an immunohistochemical study. <i>International Journal of Clinical and Experimental Pathology</i> , 2010, 3, 244-53.	0.5	19
58	Polymeric micelles for the solubilization and delivery of STAT3 inhibitor cucurbitacins in solid tumors. <i>International Journal of Pharmaceutics</i> , 2008, 347, 118-127.	2.6	81
59	Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. <i>Blood</i> , 2008, 112, 5171-5179.	0.6	82
60	Epigenetic Regulation of the WNT Canonical Pathway in Mantle Cell Lymphoma.. <i>Blood</i> , 2008, 112, 3340-3340.	0.6	0
61	Pathobiology of ALK+ anaplastic large-cell lymphoma. <i>Blood</i> , 2007, 110, 2259-2267.	0.6	236
62	Determining the Mechanism of Transformation of Follicular Lymphoma into Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2007, 110, 181-181.	0.6	5
63	Immunoglobulin VH somatic hypermutation in mantle cell lymphoma: mutated genotype correlates with better clinical outcome. <i>Modern Pathology</i> , 2006, 19, 1498-1505.	2.9	28
64	Bortezomib Activity Against Mantle Cell Lymphoma Overcomes Classic Mechanisms of Drug Resistance and Targets Cell Cycle Control.. <i>Blood</i> , 2006, 108, 4393-4393.	0.6	0
65	Bortezomib Induces an Antioxidant and ER-Stress Response Gene Expression Signature in Mantle Cell Lymphoma: Implications for Response Prediction and Optimized Chemotherapy Regimens.. <i>Blood</i> , 2006, 108, 830-830.	0.6	3
66	Transmission of a Follicular Lymphoma by Allogeneic Bone Marrow Transplantation “Evidence to Support the Existence of a Lymphoma Progenitor Cell.. <i>Blood</i> , 2006, 108, 2415-2415.	0.6	0
67	Combination Bortezomib (PS341, Velcade) and Rituximab Treatment Affects Multiple Survival and Death Pathways To Promote Apoptosis in Mantle Cell Lymphoma.. <i>Blood</i> , 2005, 106, 2407-2407.	0.6	5
68	Role of Jak3 in Chronic Myeloid Leukemia: Evidence To Identify Jak3 as a Potential Therapeutic Target.. <i>Blood</i> , 2005, 106, 2870-2870.	0.6	1
69	Cyclin D1 Expression in Dysplastic Nevi. <i>Archives of Pathology and Laboratory Medicine</i> , 2001, 125, 208-210.	1.2	25
70	Flow Cytometric Detection of CD79a Expression in T-Cell Acute Lymphoblastic Leukemias. <i>American Journal of Clinical Pathology</i> , 2000, 113, 823-830.	0.4	49
71	Sinusoidal CD30-Positive Large B-Cell Lymphoma: A Morphologic Mimic of Anaplastic Large Cell Lymphoma. <i>Modern Pathology</i> , 2000, 13, 223-228.	2.9	49
72	Coexisting Thymic and Gastric Lymphomas of Mucosa-Associated Lymphoid Tissues in a Patient With Sjögren Syndrome. <i>Archives of Pathology and Laboratory Medicine</i> , 2000, 124, 770-773.	1.2	27

#	ARTICLE	IF	CITATIONS
73	Glandular Malignant Peripheral Nerve Sheath Tumor. Archives of Pathology and Laboratory Medicine, 2000, 124, 1364-1368.	1.2	19
74	Cytodiagnosis of metastatic amelanotic melanomas by fine-needle aspiration biopsy. , 1998, 84, 92-97.		11
75	CD45 (leucocyte common antigen) expression in T and B lymphocyte subsets. Leukemia and Lymphoma, 1996, 20, 217-222.	0.6	42
76	Postnatal changes of CD45 expression in peripheral blood T and B cells. British Journal of Haematology, 1994, 87, 251-257.	1.2	13